These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 16176495)

  • 41. Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
    Ringleb PA; Bhatt DL; Hirsch AT; Topol EJ; Hacke W;
    Stroke; 2004 Feb; 35(2):528-32. PubMed ID: 14739421
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antiplatelet agents and randomized trials.
    Diener HC
    Rev Neurol Dis; 2007; 4(4):177-83. PubMed ID: 18195669
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cost effectiveness of clopidogrel in secondary cardiovascular prevention: a cost-effectiveness analysis based on the Caprie Study].
    Haldemann R; Lüscher TF; Szucs TD
    Praxis (Bern 1994); 2001 Mar; 90(13):539-45. PubMed ID: 11550619
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cost-effectiveness of clopidogrel-aspirin versus aspirin alone for acute transient ischemic attack and minor stroke.
    Pan Y; Wang A; Liu G; Zhao X; Meng X; Zhao K; Liu L; Wang C; Johnston SC; Wang Y; Wang Y;
    J Am Heart Assoc; 2014 Jun; 3(3):e000912. PubMed ID: 24904018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
    Biller J
    J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination antiplatelet agents in ischemic cerebrovascular disease.
    Moussouttas M; Papamitsakis N
    Mt Sinai J Med; 2005 Jan; 72(1):16-22. PubMed ID: 15682258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
    Ringleb PA; Schwark C; Schwaninger M; Schellinger PD
    Expert Opin Pharmacother; 2005 Mar; 6(3):359-67. PubMed ID: 15794727
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Secondary stroke prevention with antiplatelet therapy with emphasis on the cardiac patient: a neurologist's view.
    Gebel JM
    J Am Coll Cardiol; 2005 Sep; 46(5):752-5. PubMed ID: 16139120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?
    Diener HC
    Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Using triple antiplatelet therapy in patients with non-ST elevation acute coronary syndrome managed invasively: a cost-effectiveness analysis.
    Latour-Pérez J; de Miguel Balsa E; Betegón L; Badia X
    Value Health; 2008; 11(5):853-61. PubMed ID: 18489507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antiplatelet agents for prevention of recurrent ischemic stroke.
    Hegge KA
    S D Med; 2009 Jan; 62(1):15-7. PubMed ID: 19245087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Antithrombotic drugs for the secondary prevention of ischemic stroke.
    Nenci GG; Goracci S
    Ann Ital Med Int; 2000; 15(4):282-90. PubMed ID: 11202630
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
    Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
    [No Abstract]   [Full Text] [Related]  

  • 54. Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable.
    Connolly SJ; Eikelboom JW; Ng J; Hirsh J; Yusuf S; Pogue J; de Caterina R; Hohnloser S; Hart RG;
    Ann Intern Med; 2011 Nov; 155(9):579-86. PubMed ID: 22041946
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
    Schellinger PD; Jüttler E; Meyding-Lamadé UK; Schwark C
    Fortschr Neurol Psychiatr; 2004 May; 72(5):270-81. PubMed ID: 15136948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
    Prescrire Int; 2000 Jun; 9(47):82-3. PubMed ID: 11010748
    [TBL] [Abstract][Full Text] [Related]  

  • 57. What's new in stroke? The top 10 studies of 2006-2008. Part I.
    Hart RG
    Pol Arch Med Wewn; 2008 Nov; 118(11):650-7. PubMed ID: 19140569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antiplatelet drugs for ischemic stroke prevention.
    Leys D; Balucani C; Cordonnier C
    Cerebrovasc Dis; 2009; 27 Suppl 1():120-5. PubMed ID: 19342841
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MATCH results: implications for the internist.
    Lutsep HL
    Am J Med; 2006 Jun; 119(6):526.e1-7. PubMed ID: 16750967
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A cost-utility analysis of clopidogrel in patients with ST elevation acute coronary syndromes in the UK.
    Karnon J; Holmes MW; Williams R; Bakhai A; Brennan A
    Int J Cardiol; 2010 Apr; 140(3):315-22. PubMed ID: 19106007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.